Thelansis

Alzheimer’s Disease (AD) Current Treatment Insights Thelansis’s “Alzheimer’s Disease (AD) Current Treatment Insights Report – 2025″ describes the current treatment and management in Alzheimer’s Disease. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted. Key business questions answered: Patient characteristics/patient segments Patient diagnosis criteria Patient shares for current therapies Line of therapy analysis Treatment sequencing Patient journey Compliance and persistency analysis Polypharmacy Factors impacting physician choice of treatments Drivers and ba...

  Alzheimer’s Disease (AD) Current Treatment Insights Thelansis’s  “Alzheimer’s Disease (AD) Current Treatment Insights Report – 2025″  describes the current treatment and management in Alzheimer’s Disease. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted. Alzheimer’s Disease (AD) Overview Alzheimer’s disease (AD) is the foremost cause of dementia, accounting for approximately 60% to 80% of all cases of dementia. This condition is a progressive and neurodegenerative ailment characterized by three principal features within the brain: Amyloid plaques, anomalous clumps formed from prote...